doramapimod   Click here for help

GtoPdb Ligand ID: 5668

Synonyms: BIRB 796BS | BIRB-796 | BIRB796
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Doramapimod is an allosteric p38 MAP kinase inhibitor [2-3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 10
Topological polar surface area 80.13
Molecular weight 527.29
XLogP 5.11
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES O=C(Nc1cc(nn1c1ccc(cc1)C)C(C)(C)C)Nc1ccc(c2c1cccc2)OCCN1CCOCC1
Isomeric SMILES O=C(Nc1cc(nn1c1ccc(cc1)C)C(C)(C)C)Nc1ccc(c2c1cccc2)OCCN1CCOCC1
InChI InChI=1S/C31H37N5O3/c1-22-9-11-23(12-10-22)36-29(21-28(34-36)31(2,3)4)33-30(37)32-26-13-14-27(25-8-6-5-7-24(25)26)39-20-17-35-15-18-38-19-16-35/h5-14,21H,15-20H2,1-4H3,(H2,32,33,37)
No information available.
Summary of Clinical Use Click here for help
Doramapimod (as research code BIRB 796) has been assessed in Phase 2 clinical trials for plaque-type psoriasis and rheumatoid arthritis (RA). Additional trials for RA and Crohn's disease were terminated. Development of the compound has not progressed beyond Phase 2.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
p38 MAP kinases α and β are crucial in regulating the production of proinflammatory cytokines, such as tumor necrosis factor α (TNFα) and interleukin-1β. Doramapimod inhibits p38 MAP kinase activity, and has been shown to block TNFα release in LPS-stimulated THP-1 cells with an IC50 value of 18 nM [3].